Literature DB >> 17981607

Papillomavirus E6 and E7 proteins and their cellular targets.

Trisha M Wise-Draper1, Susanne I Wells.   

Abstract

The mucosal human papillomaviruses (HPVs) infect human genital and oral epithelial cells and cause lesions ranging in severity from benign to malignant. HPV associated malignancies include cervical and other anogenital cancers as well as a subpopulation of head and neck cancers. Viral infection of epidermal stem or transit amplifying cells can result in long term viral persistence, and the development of carcinogenesis over a significant amount of time then requires additional cooperating genetic hits. Only the so-called high risk HPV types mediate human carcinogenesis, whereas the low risk HPVs have been linked to benign epithelial lesions that are not generally life threatening, but nonetheless are a major health burden. Expression of the high risk HPV E6 and E7 oncogenes is sufficient for primary human keratinocyte immortalization and is required for initiation and all subsequent stages of carcinogenic progression. Together with the finding that high levels of E6/E7 are a unifying hallmark of HPV positive cancers, these two genes are presumed to be the relevant virus-derived transformation stimuli in humans. E6 and E7 proteins do not possess intrinsic enzymatic activities, but instead function though a number of direct and indirect interactions with cellular proteins, a number of which are well known cellular tumor suppressors. We will summarize here current insights into E6 and E7 interactions with specific cellular targets that stimulate aspects of the viral life cycle, interfere with cell cycle controls and promote carcinogenic processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981607     DOI: 10.2741/2739

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  72 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  White spot syndrome virus IE1 and WSV056 modulate the G1/S transition by binding to the host retinoblastoma protein.

Authors:  Xiaozhuo Ran; Xiaofang Bian; Yongchang Ji; Xiumin Yan; Feng Yang; Fang Li
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 3.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 4.  Replication and partitioning of papillomavirus genomes.

Authors:  Alison A McBride
Journal:  Adv Virus Res       Date:  2008       Impact factor: 9.937

Review 5.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

Review 6.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

7.  Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C.

Authors:  Pankaj Kumar; Masanao Murakami; Rajeev Kaul; Abhik Saha; Qiliang Cai; Erle S Robertson
Journal:  Future Virol       Date:  2009-01       Impact factor: 1.831

8.  Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance.

Authors:  Shiyuan Hong; Kavi P Mehta; Laimonis A Laimins
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

9.  The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis.

Authors:  Kim-Tat Teoh; Yu-Lam Siu; Wing-Lim Chan; Marc A Schlüter; Chia-Jen Liu; J S Malik Peiris; Roberto Bruzzone; Benjamin Margolis; Béatrice Nal
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

10.  The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42.

Authors:  A W Oliver; X He; K Borthwick; A J Donne; L Hampson; I N Hampson
Journal:  Br J Cancer       Date:  2010-12-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.